Sprint Bioscience AB (SE:SPRINT)
:SPRINT
Top Page
Sprint Bioscience AB
(SPRINT)
Select Model
Select Model
Rating:79Outperform
Price Target:
kr2.00
▲(35.14% Upside)
Action:UpgradedDate:02/18/26
Score is driven mainly by improved financial performance (strong 2025 profitability and a debt-free balance sheet) and supportive valuation (very low P/E). Technicals are positive due to a clear uptrend, but overbought momentum indicators add near-term risk.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet materially reduces refinancing and interest-rate risk, granting Sprint flexibility to fund R&D, pursue partnerships, or time licensing negotiations without immediate capital market pressure. This durability supports long-term project advancement and negotiating leverage with partners.
Negative Factors
Lumpy cash flows and uneven cash generation
Biotech milestone and licensing receipts are inherently lumpy; Sprint’s cash flow swung from negative to strongly positive in 2025. That irregularity makes multi-period planning and stable R&D funding harder, raising the probability of periodic financing needs or delayed program advancement tied to payment timing.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet materially reduces refinancing and interest-rate risk, granting Sprint flexibility to fund R&D, pursue partnerships, or time licensing negotiations without immediate capital market pressure. This durability supports long-term project advancement and negotiating leverage with partners.
Read all positive factors
Sprint Bioscience AB (SPRINT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr236.35M
Dividend YieldN/A
Average Volume (3M)560.98K
Price to Earnings (P/E)1.5
Beta (1Y)1.08
Revenue Growth-17.80%
EPS Growth-11.96%
CountrySE
Employees38
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.07
Shares Outstanding105,515,540
10 Day Avg. Volume1,502,692
30 Day Avg. Volume560,983
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.14
Price to Sales (P/S)0.81
P/FCF Ratio1.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr99.40M
Sprint Bioscience AB Business Overview & Revenue Model
Company Description
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and P...
How the Company Makes Money
Sprint Bioscience primarily generates revenue by partnering and licensing its drug discovery projects to external life-science companies. Under these collaboration and license agreements, the company can receive (i) upfront payments when a partner...
Sprint Bioscience AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
83
Very Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 167.17M | 65.64M | 50.48M | 83.00K | 35.11M |
| Gross Profit | 97.33M | 37.30M | 41.79M | -60.91M | 24.68M |
| EBITDA | 98.40M | -17.32M | 396.00K | -60.00M | -24.49M |
| Net Income | 91.74M | -18.28M | -438.00K | -60.17M | -25.35M |
Balance Sheet | |||||
| Total Assets | 136.66M | 42.05M | 62.38M | 37.42M | 79.14M |
| Cash, Cash Equivalents and Short-Term Investments | 126.70M | 25.06M | 49.93M | 29.49M | 70.64M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 17.48M | 32.78M | 34.60M | 9.23M | 8.68M |
| Stockholders Equity | 119.18M | 9.27M | 27.77M | 28.19M | 70.45M |
Cash Flow | |||||
| Free Cash Flow | 83.44M | -24.65M | 20.42M | -59.05M | -42.82M |
| Operating Cash Flow | 83.53M | -23.36M | 22.87M | -59.05M | -40.12M |
| Investing Cash Flow | -54.00K | -1.30M | -2.45M | 0.00 | -2.71M |
| Financing Cash Flow | 18.17M | -225.00K | 24.00K | 17.90M | 86.39M |
Sprint Bioscience AB Technical Analysis
Positive
1.48
Price Trends
1.88
Positive
1.55
Positive
1.06
Positive
Market Momentum
0.05
Negative
57.34
Neutral
46.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPRINT, the sentiment is Positive. The current price of 1.48 is below the 20-day moving average (MA) of 1.97, below the 50-day MA of 1.88, and above the 200-day MA of 1.06, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 57.34 is Neutral, neither overbought nor oversold. The STOCH value of 46.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SPRINT.
Sprint Bioscience AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr236.35M | 1.48 | -264.12% | ― | -17.80% | -11.96% | |
54 Neutral | kr26.23M | -4.94 | -30.39% | 11.26% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr96.73M | -14.97 | -211.04% | ― | 132.07% | 54.65% | |
43 Neutral | kr41.58M | -1.97 | ― | 8.47% | -94.12% | -25.83% | |
40 Underperform | kr19.95M | -1.19 | -88.65% | ― | 8.46% | 11.73% |
* Healthcare Sector Average
SE:SPRINT
Sprint Bioscience AB
2.24
1.55
224.64%
SE:2CUREX
2cureX AB
1.05
0.70
199.43%
SE:CMOTEC.B
Scandinavian ChemoTech AB Class B
3.80
2.66
233.33%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
5.65
-15.95
-73.84%
SE:LARK
CombiGene AB
2.10
0.06
2.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.